 Onward Phase III Clinical Trial of Adial Pharmaceuticals AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79 reduction in heavy drinking days, the primary end-points were not achieved in. 